Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes.
暂无分享,去创建一个
[1] U. Germing,et al. Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. , 2011, Leukemia research.
[2] C. Cogle,et al. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. , 2011, Blood.
[3] M. Sant,et al. Sant M, Allemani C, Tereanu C, et al; HAEMACARE Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724-3734 , 2011, Blood.
[4] F. Berrino,et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. , 2010, Blood.
[5] M. Laouri,et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] D. Steensma. Myelodysplastic Syndromes : Pathobiology and Clinical Management , 2008 .
[7] N. Howlader,et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. , 2008, Blood.
[8] A. Brett. Myelodysplastic Syndromes: Incidence and Survival , 2007 .
[9] P. Greenberg,et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. , 2006, The New England journal of medicine.
[10] L. Rimsza,et al. Efficacy of lenalidomide in myelodysplastic syndromes. , 2005, The New England journal of medicine.
[11] Deborah Schrag,et al. Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population , 2002, Medical care.
[12] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.